

Matthew S Block

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/331250/publications.pdf>

Version: 2024-02-01

53
papers

1,391
citations

430874

18
h-index

361022

35
g-index

53
all docs

53
docs citations

53
times ranked

2903
citing authors

#	ARTICLE	IF	CITATIONS
1	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 834981.	4.8	19
2	Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. , 2022, 10, e004233.		24
3	Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 520-529.	1.4	10
4	Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 537-544.	2.5	4
5	Image-guided tumor ablation in gynecologic oncology: Review of interventional oncology techniques and case examples highlighting a collaborative, multidisciplinary program. <i>Gynecologic Oncology</i> , 2021, 160, 835-843.	1.4	5
6	Sequencing chemotherapy before radiotherapy for women with stage IIIC endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 702-708.	2.5	6
7	Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer. <i>PLoS ONE</i> , 2021, 16, e0252390.	2.5	5
8	Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy. <i>American Journal of Hematology</i> , 2021, 96, E362-E367.	4.1	4
9	BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance). <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 1012-1020.	2.4	4
10	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. <i>Nature Communications</i> , 2020, 11, 5173.	12.8	46
11	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. <i>Melanoma Research</i> , 2020, 30, 364-375.	1.2	42
12	Clinical significance of SLN benign capsular nevi in patients with melanoma. <i>Journal of Surgical Oncology</i> , 2020, 122, 1043-1049.	1.7	1
13	Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. <i>ESMO Open</i> , 2020, 5, e000926.	4.5	35
14	Peptide vaccine with glucopyranosyl lipid A stable oil-in-water emulsion for patients with resected melanoma. <i>Immunotherapy</i> , 2020, 12, 983-995.	2.0	6
15	A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. <i>Onc Immunology</i> , 2020, 9, 1847846.	4.6	22
16	Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. <i>PLoS ONE</i> , 2020, 15, e0230306.	2.5	27
17	Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 646-652.	1.4	16
18	Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort. <i>Journal of Women's Health</i> , 2020, 29, 1160-1167.	3.3	21

#	ARTICLE	IF	CITATIONS
19	Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. <i>Clinical Cancer Research</i> , 2020, 26, 1045-1053.	7.0	13
20	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. <i>OncImmunity</i> , 2020, 9, 1744947.	4.6	26
21	Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors. <i>Blood</i> , 2020, 136, 31-32.	1.4	1
22	Title is missing!. , 2020, 15, e0230306.		0
23	Title is missing!. , 2020, 15, e0230306.		0
24	Title is missing!. , 2020, 15, e0230306.		0
25	Title is missing!. , 2020, 15, e0230306.		0
26	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. <i>Clinical Cancer Research</i> , 2019, 25, 5808-5817.	7.0	66
27	Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine. <i>Supportive Care in Cancer</i> , 2019, 27, 3869-3875.	2.2	9
28	The role of serum lactate dehydrogenase level as a prognostic indicator in resected, high risk melanoma. <i>Dermatologic Therapy</i> , 2019, 32, e12813.	1.7	0
29	The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. <i>Immunotherapy</i> , 2019, 11, 75-79.	2.0	20
30	Management of local or regional nonâ€œnodal disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 187-199.	1.7	8
31	A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1. <i>Melanoma Research</i> , 2019, 29, 420-427.	1.2	10
32	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
33	Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 3014-3025.	7.0	64
34	Peptide-Binding Groove Contraction Linked to the Lack of T Cell Response: Using Complex Structure and Energy To Identify Neoantigens. <i>ImmunoHorizons</i> , 2018, 2, 216-225.	1.8	8
35	Facial diplegia after pembrolizumab treatment. <i>Muscle and Nerve</i> , 2017, 56, E20-E21.	2.2	22
36	Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. <i>Gynecologic Oncology</i> , 2017, 146, 64-68.	1.4	35

#	ARTICLE	IF	CITATIONS
37	A proof-of-concept trial of protein kinase C δ inhibition with auranofin for the paclitaxel-induced acute pain syndrome. <i>Supportive Care in Cancer</i> , 2017, 25, 833-838.	2.2	7
38	IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. <i>Cancer Research</i> , 2017, 77, 6667-6678.	0.9	126
39	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
40	Inflammatory and Nutritional Serum Markers as Predictors of Peri-operative Morbidity and Survival in Ovarian Cancer. <i>Anticancer Research</i> , 2017, 37, 3673-3677.	1.1	28
41	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. <i>JCI Insight</i> , 2016, 1, .	5.0	68
42	Ureteral obstruction in cancer patients: a qualitative study. <i>Psycho-Oncology</i> , 2016, 25, 605-609.	2.3	3
43	Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2016, 114, 1412-1420.	6.4	8
44	Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic Melanoma. <i>Mayo Clinic Proceedings</i> , 2016, 91, 288-296.	3.0	17
45	Treatment of HIV/AIDS associated cancers with immunotherapy targeting PD-1/PD-L1 instead of chemotherapy. <i>Medical Hypotheses</i> , 2016, 86, 129-131.	1.5	2
46	Second-line dovitinib in metastatic endometrial cancer. <i>Lancet Oncology</i> , The, 2015, 16, 604-606.	10.7	2
47	Plasma immune analytes in patients with epithelial ovarian cancer. <i>Cytokine</i> , 2015, 73, 108-113.	3.2	31
48	Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 22-30.	0.9	157
49	Tumor Hypomethylation at 6p21.3 Associates with Longer Time to Recurrence of High-Grade Serous Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 3084-3091.	0.9	32
50	Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. <i>Melanoma Research</i> , 2011, 21, 438-445.	1.2	17
51	Differential Response of Human and Mouse Dendritic Cells to VEGF Determines Interspecies Discrepancies in Tumor-Mediated Th1/Th2 Polarity Shift. <i>Clinical Cancer Research</i> , 2011, 17, 1776-1783.	7.0	19
52	Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 335-8.	0.3	4
53	MHC Class I Gene Conversion Mutations Alter the CD8 T Cell Repertoire. <i>Journal of Immunology</i> , 2003, 171, 4006-4010.	0.8	9